dabigatran etexilate
dabigatran etexilate: 4 clinical trials tracked.
dabigatran etexilate evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about dabigatran etexilate, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 3 study sponsors
Clinical Trial Registry Records (4)
A Phase 1, Open-label, Fixed-sequence Trial in Healthy Participants to Assess the Drug Interaction Potential of BGB-43395 With A Drug Cocktail Representative for CYP3A4, CYP2C9, P-gp, and BCRP Substrates
Primary endpoint: Area Under the Concentration Time Curve from Time Zero to Infinity (AUC0-inf)
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986533 in Healthy Participants, an Open-label Assessment of Food and pH Effects on the Relative Bioavailability of BMS-986533, and an Open-label Study to Evaluate P-gp- and BCRP-mediated Drug-Drug Interaction Potential of BMS-986533 in Healthy Participants
Primary endpoint: Number of participants with Adverse Events (AE)
AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With ARV-471
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)
Primary endpoint: Primary safety endpoint - first major or clinically relevant non-major bleeding event, as defined by the ISTH